Ustekinumab, Inhibitor

Ustekinumab

Cat. Num. AAA5759558

• Purity: 99.4%
• Synonyms: Ustekinumab; Anti-Human IL-12/IL-23; inhibitor

• Purity/Purification: 99.4%
• Form/Format: Solid. Powder

• Solubility: <1mg/ml refers to the product slightly soluble or insoluble
• CAS Number: 815610-63-0
• Target & IC50: IL-12; IL-23
• Cell Research: HUVECs are grown on calibrated glass coverslips to a confluency of 80%. Subsequently, cells are incubated with 200ug/mL Ustekinumab AlexaFluor488 and Briakinumab AlexaFluor594 for 20 minutes at 37 degree C, pH 7.3, washed three times, and chased in fresh medium for an additional 20 min before fixation. Antibodies are directly labeled. FcRn binding is quality controlled by SPR analysis. Cells are then counterstained with anti-FcRn monoclonal antibody DVN22, followed by anti-mouse secondary antibodies conjugated to AlexaFluor647. Imaging is performed on a Leica SP8 confocal microscope[2].
• Preparation and Storage: Store at -20 degree C for 3 years powder; -80 degree C for 2 years in solvent

Related Product Information for Ustekinumab, inhibitor

Ustekinumab is an anti-IL-12/IL-23 IgG1kappa human monoclonal antibody.

References

Montepaone M, et al. Profile of ustekinumab and its potential in the treatment,of active psoriatic arthritis. Open Access Rheumatol. 2014 Feb 20;6:7-13.
Montepaone M, et al. Profile of ustekinumab and its potential in the treatment,of active psoriatic arthritis. Open Access Rheumatol. 2014 Feb 20;6:7-13.
Schoch A, et al. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics. Proc Natl Acad Sci U S A. 2015 May 12;112(19):5997-6002.
Schoch A, et al. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics. Proc Natl Acad Sci U S A. 2015 May 12;112(19):5997-6002.